Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

Skin Lesion Clinical Trial

Official title:

A Multicenter, Prospective, Randomized, Comparison IDE Study Between the Pulse Biosciences CellFX System and Electrodessication (Hyfrecator Electrosurgical) for the Treatment of Sebaceous Hyperplasia (SH) Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04539886
• Other study ID #: NP-SC-012
• Status: Completed
• Phase: N/A
• Start date: September 28, 2020
• Est. completion date: November 18, 2021

Study information

• Verified date: April 2024
• Source: Pulse Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.

Description:

This SH comparative study will evaluate safety and efficacy in a split face design using the CellFX System and pre-defined energy profile for all primary and secondary treatments based on Fitzpatrick Skin Types and tip size. The comparator group will be treated with the same standardized intralesional electrodesiccation procedure conducted by all participating clinical sites. Subjects with 4-10 qualifying SH lesions on the face except the scalp, nose and within the orbital region will be enrolled. Each subject will be evaluated by the blinded site investigator at 7-days, 30-days, and 60-days post-initial CellFX and Electrodessication treatments. At the 30-day follow-up visit, lesions will be evaluate using Global Aesthetic Improvement Scale (GAIS), for eligibility to receive an additional treatment. In case of a second treatment, the subject will be evaluated by the blinded site investigator at 30-days and 60-days post-retreatment. Photography of the study lesions will be captured along with the blinded site investigator assessments at all visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 18, 2021
• Est. primary completion date: February 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is at least 21 and no older than 80 years of age.
• Subject gives voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
• Subject must comply with study procedures including follow-up visits.
• Subject is willing to have SH lesions treated in a single treatment session and understands that their lesion(s) may undergo a second treatment session at a subsequent visit.
• Subject must have a minimum of four SH lesions and up to 10 SH lesions to be treated and the subject must have at least two SH lesions located on each side of the face.
• For study purposes, the SH lesions must be no greater than 2 mm in height and must not exceed 5 mm x 5 mm at their largest dimension. The subject's lesions cannot be located within the eye orbit, nose, or scalp.
• Subject consents to have photographs taken of the SH lesion(s).
• Subject agrees to refrain from using all other lesion removal products or treatments (e.g. retinols, retinoids, and exfoliating products) to the treated SH lesions or any new SH lesions during the study period.
• Subject agrees to refrain from prolonged sun exposure during the study period.

Exclusion Criteria:

• Subject has an implantable electronic medical device.(i.e., pacemaker, implantable cardioverter defibrillator)
• Subject has an active infection or history of infection in designated test area within 90 days prior to first treatment.
• Subject is not willing or able to sign the Informed Consent.
• Subject is known to be immune compromised.
• Subject is prone to developing hypertrophic scars or to be a keloid producer.
• Subject has allergies to Lidocaine or Lidocaine-like products.
• Subject is employed by the sponsor, clinic site, or entity associated with the conduct of the study.
• Have any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study.
• Use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study.
• Subject was previously treated with CellFX for SH lesions.

Related Conditions & MeSH terms

• Hyperplasia
• Sebaceous Hyperplasia
• Skin Abnormalities
• Skin Lesion

Intervention

Device:
• CellFX System
CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
• Intralesional Electrodesiccation
Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode

Locations

Country	Name	City	State
United States	Dermatology, Laser & Vein Specialists of the Carolinas, PLLC	Charlotte	North Carolina
United States	Zel Skin & Laser Specialists	Edina	Minnesota
United States	Austin Institute for Clinical Research, Inc.	Houston	Texas
United States	Austin Institute for Clinical Research, Inc.	Pflugerville	Texas
United States	Investigate MD, LLC	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Pulse Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Lesions With Improvement as Assessed With the Global Aesthetic Improvement Scale (GAIS)	Percentage of SH Lesions with Improvement as Assessed by Blinded Investigator During Live Assessments based on Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale ranges from 1=Very Much Improved or Excellent Corrective Result to 5=Worsened Appearance Compared with Original Condition. The primary effectiveness endpoint of improvement at 60-days post-last treatment as assessed "live" by the blinded site investigator using the 5-point GAIS	60 days post last CellFX or Electrodessication treatment, up to a maximum of 3 months.
Primary	Percentage of Lesions With Hyperpigmentation, Hypopigmentation and Scarring as Assessed by Blinded Investigator During Live Assessments	The first co-primary safety endpoint includes the percentage of lesions showing hyperpigmentation and scarring as assessed by the blinded Investigator at 60 days after the last treatment with CellFX or Electrodessication	60 days post last CellFX or Electrodessication treatment, up to a maximum of 3 months.
Primary	Percentage of Lesions With Skin Textual Changes as Assessed by Blinded Investigator During Live Skin Assessment	The second co-primary safety endpoint of skin textural changes including; flaking, erythema, crusting, scabbing, or other skin irregularities was assessed by the blinded site investigator at 30 days post last CellFX or Electrodessication treatment.	30 days post last CellFX or Electrodessication treatment, up to a maximum of 2 months